Compare TNON & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNON | XAIR |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 10.5M |
| IPO Year | 2022 | N/A |
| Metric | TNON | XAIR |
|---|---|---|
| Price | $1.11 | $1.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | ★ $11.00 |
| AVG Volume (30 Days) | 125.7K | ★ 165.1K |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,233,000.00 | ★ $5,802,000.00 |
| Revenue This Year | $19.56 | $128.45 |
| Revenue Next Year | $71.06 | $153.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 147.74 |
| 52 Week Low | $0.85 | $1.00 |
| 52 Week High | $5.85 | $11.20 |
| Indicator | TNON | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 45.73 | 32.96 |
| Support Level | $1.10 | $1.00 |
| Resistance Level | $1.15 | $1.31 |
| Average True Range (ATR) | 0.05 | 0.12 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 62.50 | 32.94 |
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.